YOKNEAM, Israel, Aug. 1, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events in August:
Canaccord Genuity's 43rd Annual Growth Conference
Presenters: Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: In-person fireside chat moderated by Kyle Rose, Senior Equity Analyst, and one-on-one meetings
Location: Boston, MA
When: Wednesday, Aug. 9 at 12:30 pm ET
A live webcast of the presentation can be accessed here.
Needham Virtual MedTech & Diagnostics 1x1 Conference
Presenters: Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: Virtual one-on-one meetings
When: Monday, Aug. 14
UBS Med Device Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetings
Location: Dana Point, CA
When: Tuesday, Aug. 15 at 9:00 am PT
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
| Last Trade: | US$17.08 |
| Daily Change: | -0.11 -0.64 |
| Daily Volume: | 1,912,263 |
| Market Cap: | US$1.300B |
September 04, 2024 August 06, 2024 July 31, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
